Go online to PeerView.com/QRQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of renal cell carcinoma (RCC) continues to expand rapidly with the addition of novel targeted, immune-based, and tyrosine kinase inhibitors (TKIs) to the treatment armamentarium. Most recently, these advances have included the validation of novel combinatorial approaches, such as dual checkpoint inhibition and immunotherapy plus targeted agents (which have led to FDA approvals). Oncology professionals are increasingly challenged to adopt a more nuanced and personalized approach to selecting and sequencing the available treatment options throughout the advanced RCC continuum while taking relevant patient-, disease-, and treatment-related factors into account. During this PeerView Live CME/MOC-certified web broadcast, an expert faculty panel in RCC will share insights on recent clinical trends and how to effectively navigate a complex therapeutic landscape to leverage the potency of newer agents across different disease settings. Upon completion of this activity, participants should be better able to: Summarize updated efficacy and safety evidence on the use of multi-targeted tyrosine kinase inhibitors/anti-VEGF agents, immune checkpoint inhibitors, and novel combination approaches in the management of advanced and/or resectable renal cell carcinoma (RCC), Select individualized frontline treatment regimens utilizing targeted and immune-based options for patients with advanced RCC based on relevant patient- and disease-related characteristics, Develop regimens with novel components for patients with pretreated advanced RCC over multiple lines of therapy based on consideration of prior treatment history and patient comorbidities, Manage treatment-related complications with targeted agents and immunotherapy in patients with RCC.
View all episodes
